PillRx only · Suspension · Oral
Erythromycin Ethylsuccinate
Brands: Ery-Ped · Erythromycin Ethylsuccinate
4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US7 NDCs
4 active makers
4 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$2.994
Latest avg · Jul 22, 2026
-53%
Since Jan 22, 2025
4
Active US suppliers
57%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
6.8K
Rx · 2026 Q1
1.4M
Units dispensed
-9%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it4 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Nivagen Pharmaceuticals, Inc. | unknown | 2 | SUPPLYING |
| Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) | unknown | 2 | SUPPLYING |
| Wilshire Pharmaceuticals, Inc. | unknown | 2 | SUPPLYING |
| Carnegie Pharmaceuticals LLC | unknown | 1 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.